Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...
Hosted on MSN2h
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
With thousands of press releases published each week, it can be difficult to keep up with everything on. To help healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback